ReviewDrugs & aging2005
Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
Review in Drugs & aging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Naftidrofuryl for intermittent claudication.The Cochrane database of systematic reviews · 2012Pooled it
- Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.BMJ (Clinical research ed.) · 2009Pooled it
- Recent Advances in Single-Electron-Transfer-Mediated Carbonylation.Chemical reviews · 2026Review
- Review
- Solubility, Permeability, and Dissolution Rate of Naftidrofuryl Oxalate Based on BCS Criteria.Pharmaceutics · 2020Article
- Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia.Current treatment options in cardiovascular medicine · 2016Review
- Acute kidney injury associated with nafronyl oxalate overdose.Clinical and experimental nephrology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naftidrofuryl (Praxilene) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment effect has been controversial. Recent randomised, double-blind, placebo-controlled trials, however, have generally been conducted in accordance with updated methodology guidelines. In these studies, naftidrofuryl 200mg three times daily improved pain-free and maximal walking distances and health-related quality of life by a significantly greater extent than placebo in patients with intermittent claudication. The magnitude of these effects appears to support claims that the effects of naftidrofuryl are clinically relevant in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.